A Phase I/II Trial of Fairly Brief Androgen Suppression and Stereotactic Radiation Therapy for High-Risk Prostate Cancer (FASTR-2): Preliminary Results and Toxicity Analysis

A Phase I/II Trial of Fairly Brief Androgen Suppression and Stereotactic Radiation Therapy for High-Risk Prostate Cancer (FASTR-2): Preliminary Results and Toxicity Analysis

Purpose: FASTR was designed to provide a compact treatment course for high-risk prostate cancer patients but was discontinued because of excess toxicity. We present the results of FASTR-2, which used a lower dose to the prostate (35 Gy vs 40 Gy), smaller posterior PTV margin (4 mm vs 5 mm) and omitt...

Full description

Bibliographic Details
Main Authors: Laura Callan, MD, MASc, Glenn Bauman, MD, Jeff Chen, PhD, Michael Lock, MD, Tracy Sexton, MD, PhD, David D'Souza, MD, George Rodrigues, MD, PhD
Format: Article
Language:English
Published: Elsevier 2019-10-01
Series:Advances in Radiation Oncology
Online Access:http://www.sciencedirect.com/science/article/pii/S2452109419300910

Internet

http://www.sciencedirect.com/science/article/pii/S2452109419300910

Similar Items